Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi 2Q: Dupixent's First Set Of Sales Are On Track

Executive Summary

No surprises from Sanofi in the second quarter as sales of its flagship diabetes drug continue to fall – but a strong performance from recently launched Dupixent provided the French pharma with a refreshing reprieve in its earnings update.

You may also be interested in...



AstraZeneca Respiratory Head: Tezepelumab Could Be 'Game Changer'

AstraZeneca's first in class biologic tezepelumab, which targets TSLP, has revolutionary potential in treating severe asthma, the UK drug maker's respiratory head tells Scrip.

PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes

Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.

Regeneron And Sanofi Antibody Discovery Deal To End

Regeneron and Sanofi have decided to call it a day on their antibody discovery partnership that brought the world Praluent, Dupixent and Kevzara. Regeneron announced that the collaboration was winding down during its Q2 results, where investors were focused on Dupixent's launch progress.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel